Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001149 | 0.88 | SMN1; SMN2 (0.62) | HDAC1HDAC8HDAC3HDAC2NCOR2 | |
| SCHEMBL16596169 | 0.84 | NAAA (0.69) | HPGDSMN1; SMN2L3MBTL1MAPTCYP2C9 | |
| SCHEMBL12031270 | 0.84 | SMN1; SMN2 (0.60) | HDAC1HDAC8HDAC3HDAC2NCOR2 | |
| SCHEMBL6360275 | 0.83 | DRD2 (0.78) | HDAC1HDAC8HDAC3HDAC2NCOR2 | |
| SCHEMBL3571218 | 0.80 | KMT2A (0.57) | HPGDSMN1; SMN2L3MBTL1MAPTERCC5 | |
| SCHEMBL7166265 | 0.78 | ALDH1A1 (0.59) | HDAC1HPGDSMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL1004988 | 0.78 | DRD2 (0.81) | HDAC1HDAC8HDAC3HDAC2NCOR2 | |
| SCHEMBL6606979 | 0.77 | L3MBTL1 (0.79) | HDAC1HDAC8HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL27182280 | 0.76 | ERCC5 (0.77) | HDAC1HDAC8HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL4453789 | 0.76 | L3MBTL1 (0.77) | HDAC1HDAC8HDAC3HDAC2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670460-B1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-7517900-B2 | Pyrazole derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1670460-A4 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1670460-A2 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037199-A2 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050080087-A1 | Pyrazole derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080087-A1 | Pyrazole derivatives as cannabinoid receptor modulators | CNR1, CNR2, NPY1R | HDAC1 944/4885HDAC8 1833/4885HDAC3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.